LENZ THERAPEUTICS INC (LENZ) Stock Price, Forecast & Analysis
NASDAQ:LENZ • US52635N1037
LENZ Key Statistics, Chart & Performance
The current stock price of LENZ is 12.88 USD. In the past month the price decreased by -29%. In the past year, price decreased by -48.93%.
LENZ Technical Analysis
LENZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LENZ. While LENZ has a great health rating, there are worries on its profitability.
LENZ Financial Highlights
Over the last trailing twelve months LENZ reported a non-GAAP Earnings per Share(EPS) of -2.09. The EPS increased by 70.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.11% | ||
| ROE | -25.39% | ||
| Debt/Equity | 0 |
LENZ Forecast & Estimates
13 analysts have analysed LENZ and the average price target is 54.06 USD. This implies a price increase of 319.72% is expected in the next year compared to the current price of 12.88.
LENZ Ownership
LENZ Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LENZ
Company Profile
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 42 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Company Info
LENZ THERAPEUTICS INC
201 Lomas Santa Fe Drive, Suite 300
Solana Beach CALIFORNIA US
Employees: 42
Phone: 18589257000
LENZ THERAPEUTICS INC / LENZ FAQ
Can you describe the business of LENZ THERAPEUTICS INC?
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 42 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Can you provide the latest stock price for LENZ THERAPEUTICS INC?
The current stock price of LENZ is 12.88 USD. The price decreased by -0.69% in the last trading session.
What is the dividend status of LENZ THERAPEUTICS INC?
LENZ does not pay a dividend.
How is the ChartMill rating for LENZ THERAPEUTICS INC?
LENZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists LENZ stock?
LENZ stock is listed on the Nasdaq exchange.
How is the market expecting LENZ stock to perform?
13 analysts have analysed LENZ and the average price target is 54.06 USD. This implies a price increase of 319.72% is expected in the next year compared to the current price of 12.88.
When does LENZ THERAPEUTICS INC (LENZ) report earnings?
LENZ THERAPEUTICS INC (LENZ) will report earnings on 2026-03-09, after the market close.